News Image

Investors seeking growth at a reasonable cost should explore NASDAQ:CORT.

By Mill Chart

Last update: Mar 29, 2024

Our stock screener has spotted CORCEPT THERAPEUTICS INC (NASDAQ:CORT) as a growth stock which is not overvalued. NASDAQ:CORT is scoring great on several growth aspects while it also shows decent health and profitability. At the same time it remains remains attractively priced. We'll dive into each aspect below.

Assessing Growth for NASDAQ:CORT

ChartMill assigns a proprietary Growth Rating to each stock. The score is computed by evaluating various growth aspects, like EPS and revenue growth. We take into account the history as well as the estimated future numbers. NASDAQ:CORT was assigned a score of 7 for growth:

  • Looking at the last year, CORT shows a very strong growth in Revenue. The Revenue has grown by 20.03%.
  • Measured over the past years, CORT shows a quite strong growth in Revenue. The Revenue has been growing by 13.94% on average per year.
  • Based on estimates for the next years, CORT will show a very strong growth in Earnings Per Share. The EPS will grow by 28.28% on average per year.
  • The Revenue is expected to grow by 14.98% on average over the next years. This is quite good.
  • The EPS growth rate is accelerating: in the next years the growth will be better than in the last years.

A Closer Look at Valuation for NASDAQ:CORT

To assess a stock's valuation, ChartMill utilizes a Valuation Rating on a scale of 0 to 10. This comprehensive assessment considers various valuation aspects, comparing price to earnings and cash flows, while factoring in profitability and growth. NASDAQ:CORT has achieved a 6 out of 10:

  • Based on the Price/Earnings ratio, CORT is valued cheaply inside the industry as 82.09% of the companies are valued more expensively.
  • Based on the Price/Forward Earnings ratio, CORT is valued a bit cheaper than 79.10% of the companies in the same industry.
  • Compared to the rest of the industry, the Enterprise Value to EBITDA ratio of CORT indicates a rather cheap valuation: CORT is cheaper than 80.60% of the companies listed in the same industry.
  • Based on the Price/Free Cash Flow ratio, CORT is valued cheaply inside the industry as 83.08% of the companies are valued more expensively.
  • CORT has an outstanding profitability rating, which may justify a higher PE ratio.
  • CORT's earnings are expected to grow with 29.87% in the coming years. This may justify a more expensive valuation.

Assessing Health for NASDAQ:CORT

To gauge a stock's financial health, ChartMill utilizes a Health Rating on a scale of 0 to 10. This comprehensive evaluation encompasses liquidity and solvency, both in absolute terms and in comparison to industry peers. NASDAQ:CORT has earned a 9 out of 10:

  • An Altman-Z score of 16.56 indicates that CORT is not in any danger for bankruptcy at the moment.
  • With an excellent Altman-Z score value of 16.56, CORT belongs to the best of the industry, outperforming 91.04% of the companies in the same industry.
  • There is no outstanding debt for CORT. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
  • CORT has a Current Ratio of 4.39. This indicates that CORT is financially healthy and has no problem in meeting its short term obligations.
  • With a decent Current ratio value of 4.39, CORT is doing good in the industry, outperforming 60.20% of the companies in the same industry.
  • A Quick Ratio of 4.31 indicates that CORT has no problem at all paying its short term obligations.
  • The Quick ratio of CORT (4.31) is better than 60.70% of its industry peers.

Understanding NASDAQ:CORT's Profitability

ChartMill assigns a Profitability Rating to every stock. This score ranges from 0 to 10 and evaluates the different profitability ratios and margins, both absolutely, but also relative to the industry peers. NASDAQ:CORT scores a 8 out of 10:

  • With an excellent Return On Assets value of 17.08%, CORT belongs to the best of the industry, outperforming 96.02% of the companies in the same industry.
  • Looking at the Return On Equity, with a value of 20.95%, CORT belongs to the top of the industry, outperforming 92.04% of the companies in the same industry.
  • CORT's Return On Invested Capital of 17.91% is amongst the best of the industry. CORT outperforms 95.02% of its industry peers.
  • Measured over the past 3 years, the Average Return On Invested Capital for CORT is significantly above the industry average of 16.07%.
  • CORT's Profit Margin of 22.01% is amongst the best of the industry. CORT outperforms 93.03% of its industry peers.
  • CORT has a Operating Margin of 22.26%. This is amongst the best in the industry. CORT outperforms 90.05% of its industry peers.
  • Looking at the Gross Margin, with a value of 98.66%, CORT belongs to the top of the industry, outperforming 98.01% of the companies in the same industry.

Every day, new Affordable Growth stocks can be found on ChartMill in our Affordable Growth screener.

Our latest full fundamental report of CORT contains the most current fundamental analsysis.

Disclaimer

Important Note: The content of this article is not intended as trading advice. It is essential to perform your own analysis and exercise caution when making trading decisions. The article presents observations created by automated analysis but does not guarantee any trading or investment outcomes. Always trade responsibly and make independent judgments.

Back

CORCEPT THERAPEUTICS INC

NASDAQ:CORT (4/24/2024, 7:00:00 PM)

After market: 22.48 0 (0%)

22.48

-0.52 (-2.26%)

CORT News

News Image15 hours ago - Corcept Therapeutics IncorporatedCorcept Therapeutics to Announce First Quarter Financial Results, Provide Corporate Update and Host Conference Call
News Image15 hours ago - Corcept Therapeutics IncorporatedCorcept Therapeutics to Announce First Quarter Financial Results, Provide Corporate Update and Host Conference Call

MENLO PARK, Calif., April 24, 2024 (GLOBE NEWSWIRE) -- Corcept Therapeutics Incorporated (NASDAQ: CORT) today announced it will report first quarter...

News Image3 days ago - Market News VideoNotable Monday Option Activity: RIOT, SIG, CORT
News Image3 days ago - Corcept Therapeutics IncorporatedCorcept Announces Positive Results From Open-Label Portion of Pivotal Phase 3 GRACE Trial in Patients With Cushing’s Syndrome
News Image6 days ago - ChartmillWhile growth is established for NASDAQ:CORT, the stock's valuation remains reasonable.

For those who appreciate growth without the sticker shock, CORCEPT THERAPEUTICS INC (NASDAQ:CORT) is worth considering.

News Image10 days ago - Corcept Therapeutics IncorporatedCorcept Completes Enrollment in Phase 2 DAZALS Trial in Patients With Amyotrophic Lateral Sclerosis (ALS)
News Image10 days ago - Corcept Therapeutics IncorporatedCorcept Completes Enrollment in Phase 2 DAZALS Trial in Patients With Amyotrophic Lateral Sclerosis (ALS)

MENLO PARK, Calif., April 15, 2024 (GLOBE NEWSWIRE) -- Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the...

News Image17 days ago - Corcept Therapeutics IncorporatedCorcept Completes Enrollment in Pivotal Phase 3 Rosella Trial of Relacorilant in Patients With Platinum-Resistant Ovarian Cancer
News Image24 days ago - Corcept Therapeutics IncorporatedCorcept Completes Enrollment in Phase 3 Gradient Trial of Relacorilant in Patients With Adrenal Cushing’s Syndrome
News Image24 days ago - Corcept Therapeutics IncorporatedCorcept Completes Enrollment in Phase 3 Gradient Trial of Relacorilant in Patients With Adrenal Cushing’s Syndrome

MENLO PARK, Calif., April 01, 2024 (GLOBE NEWSWIRE) -- Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the...

News Imagea month ago - Market News VideoNotable Monday Option Activity: GME, LULU, CORT
News Image2 months ago - Seeking AlphaCorcept Therapeutics GAAP EPS of $0.28 beats by $0.02, revenue of $135.4M beats by $6.1M (NASDAQ:CORT)

Corcept Therapeutics reports Q4 2023 financial results, with GAAP EPS of $0.28 beating expectations by $0.02 and revenue of $135.4M surpassing estimates by...

CORT Links
Follow us for more